Actinogen Medical Management
Management criteria checks 2/4
Actinogen Medical's CEO is Steve Gourlay, appointed in Mar 2021, has a tenure of 3.75 years. total yearly compensation is A$754.11K, comprised of 54.7% salary and 45.3% bonuses, including company stock and options. directly owns 4.23% of the company’s shares, worth A$3.12M. The average tenure of the management team and the board of directors is 2.3 years and 7 years respectively.
Key information
Steve Gourlay
Chief executive officer
AU$754.1k
Total compensation
| CEO salary percentage | 54.7% |
| CEO tenure | 3.8yrs |
| CEO ownership | 4.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 7yrs |
Recent management updates
Recent updates
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Apr 30
Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Nov 16Is Actinogen Medical (ASX:ACW) In A Good Position To Invest In Growth?
Aug 02We Think Actinogen Medical (ASX:ACW) Can Afford To Drive Business Growth
Apr 12We're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash Wisely
Nov 28Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Aug 09Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
Apr 07We're Not Worried About Actinogen Medical's (ASX:ACW) Cash Burn
Oct 24Actinogen Medical (ASX:ACW) Is In A Strong Position To Grow Its Business
Jul 11We're Interested To See How Actinogen Medical (ASX:ACW) Uses Its Cash Hoard To Grow
Mar 27How Does Actinogen Medical's (ASX:ACW) CEO Pay Compare With Company Performance?
Jan 07
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$754k | AU$412k | -AU$13m |
| Mar 31 2024 | n/a | n/a | -AU$14m |
| Dec 31 2023 | n/a | n/a | -AU$15m |
| Sep 30 2023 | n/a | n/a | -AU$13m |
| Jun 30 2023 | AU$657k | AU$396k | -AU$11m |
| Mar 31 2023 | n/a | n/a | -AU$11m |
| Dec 31 2022 | n/a | n/a | -AU$11m |
| Sep 30 2022 | n/a | n/a | -AU$10m |
| Jun 30 2022 | AU$955k | AU$376k | -AU$9m |
| Mar 31 2022 | n/a | n/a | -AU$8m |
| Dec 31 2021 | n/a | n/a | -AU$7m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$271k | AU$112k | -AU$4m |
Compensation vs Market: Steve's total compensation ($USD470.03K) is above average for companies of similar size in the Australian market ($USD289.43K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Gourlay (65 yo)
3.8yrs
Tenure
AU$754,111
Compensation
Dr. Steven G. Gourlay, also known as Steve, MBBS (M.D.), Ph D., FRACP, M.B.A., serves as Chief Executive Officer at Actinogen Medical Limited since March 15, 2021 and as its Managing Director and Director...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.8yrs | AU$754.11k | 4.23% A$ 3.1m | |
| Chief Financial Officer | less than a year | AU$476.62k | 0.013% A$ 9.6k | |
| Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 1.8yrs | AU$913.27k | no data | |
| Head of Investor Relations & Corporate Communications | 3.6yrs | no data | no data | |
| Head of Clinical Pharmacology & Lead Physician and Depression | 2.8yrs | AU$191.66k | no data | |
| Head of Manufacturing | 1.3yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data | |
| Company Secretary | 11.2yrs | no data | no data |
2.3yrs
Average Tenure
63yo
Average Age
Experienced Management: ACW's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.8yrs | AU$754.11k | 4.23% A$ 3.1m | |
| Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board | 2.9yrs | AU$913.27k | no data | |
| Independent Non-Executive Director | 7yrs | AU$114.27k | 0.44% A$ 327.4k | |
| Independent Non-Executive Chairman | 7.8yrs | AU$234.39k | 0.67% A$ 492.5k | |
| Member of Xanamem Clinical Advisory Board | 9.8yrs | no data | no data | |
| Member of Xanamem Clinical Advisory Board | 9.8yrs | no data | no data | |
| Independent Non-Executive Director | 5.7yrs | AU$114.27k | 0.27% A$ 196.1k | |
| Member of Depression & Cognition Clinical Advisory Board | 2.9yrs | no data | no data | |
| Chairman of Xanamem Clinical Advisory Board | 9.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.0yrs
Average Tenure
71yo
Average Age
Experienced Board: ACW's board of directors are considered experienced (7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 12:00 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Actinogen Medical Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Speranza | Bell Potter |
| Pooya Hemami | Edison Investment Research |